← Back to all trials
Completed
NCT06839443
Deep Learning in the Detection and Prediction of Hydroxychloroquine Maculopathy
Conditions: Hidroxicloroquine Intake
Sex: All
Ages: 18 Years – 100 Years
Healthy volunteers: Yes
Enrollment: 100
Sponsor: Centro Hospitalar de Lisboa Central
Location: Local de Saúde São José Portugal
Summary
Hydroxychloroquine retinal toxicity affects a significant number of patients using this medication. Detection of toxicity is difficult in the early stages of the disease and depends on the subjectivity of the clinician who reads the tests (optical coherence tomography, autofluorescence and visual fields). Automating the reading of these diagnostic exams could lead to earlier detection of this pathology and reduce the burden associated with interpreting these exams in the ophthalmology service. The images that are usually taken in the screening and monitoring of hydroxychloroquine toxicity by will be collected - photography of the ocular fundus and optical coherence tomography with autofluorescence.
Eligibility Criteria
Inclusion Criteria:
* Patients with HCQ intake
Exclusion Criteria:
* Patients with ocular diseases that might mimic HCQ maculopathy or interfer with HCQ maculopathy screening
Source: ClinicalTrials.gov (NCT06839443). StuddyBuddy aggregates publicly available trial information.